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The et&t of recablvm (WY42,362,, P “WV dW IC anti. 
arrhythmic drug, on ventrtculnr deRbrllk&n was cvslu. 
ated with use of implanted suupiior vata caw and left 
ventricular patch electrodes in 17 normal dogs soesthetlxd 
with sodium pentobsrbitrd. The energy rtqulred for P 56% 
pmbabttlty of succeMut defibrillation (E,I was used as the 
tndex of ventrtculsr defibrillation IhreshoM. The dogs were 
classified into three gnwps: a saline grwp (n = 6), P low 
dose recainam grwp (n = 6) and a bigb dc&e recainam 
group (n = 5). The low dose illusion invdved an inhxve. 
nous I-ding duve of 3.75 rngkg body wtlght over 20 mlo 
followed by a matntmmnce tnfuston of 0.0375 mgikg per 
min. The high dose inl”slon WLT dauMe thcsr rates. 
The low dc.se recairnam InfusIon produced a ptasmn 
rainam concentration f3.1 t 0.3 &mt and rtgnt6catttly 
increased QRS duration by Lt.3 2 3% during sinus 
rhythm. The high dose recalnam MasIan produced a 
plasma concatmtim of 7.7 * 0.9 &I and signittesntty 
increased Qlls duratian by 27 t 7% in sinus rhythm. 
Recnlnam did not change &rtcul~r effective Mr&tory 
period or sinus cycle tength. The mean change in Era 
between coatrot and infusian periods was I * 5% in the 
saline group (8.5 f 1.4 versas 8.6 * 1.6 jouks); 42 + 11% 
intbelowd~~~group~.l~l.Ovrnus11.3a11 
jou*s)nnd92 f 17% In the hlghdoserccalnsmgmup(ll.2 
+ 2.1 versus 20.5 + 2.5 joules). The changes In E, tn the 
two recabmm group8 “we signWcan$ dlUerent from tbme 
in the saline grcup and from each other (p < 0.05). It is 
mnchhifd that rtcalnam elevates the energy rquked for 
ventrictdar de6hrillatiin tn a dose.depn&nt ,,,a,mw. 
U Am Cdl &rdiol1988;12:746-52) 
Recainam (WY-42.362) is a new antiarrhythmic drug that is 
under investigation for the treatment of ventricular arrhytb- 
mias (l-5). It is classified as a class IC drug because it slows 
ventricular conduction but has little effect on the effective 
refractory period (6-g). Several experimental reports (9-m 
have indicaled that class I antiarrhythmic drugs can increase 
the energy level required for successful defibrillation. These 
effects may have therapeutic implications for patients being 
treated with an automatic implantable cardioverter- 
defibrillator. most of whom also receive antiarrhythmic 
drugs to decrease the number or rate of venlricular arrhyth- 
mias (IK). Because the output of the cardioverter- 
defibrillator is limited, an increase in the defibrillation 
threshold could lead to unsuccessful defibrillation. Several 
clinical repons (l&20) have suggested that in some patients 
antiarrhythmic drugs may have created resistance to cardio- 
version with the automatic defibrillation. However, con- 
trolled studies of drug effects on defibrillation would be 
difficult to undertake in patients. 
Bahhs (21) proposed that blockade of sodium channels is 
the mechanism by which many type 1 drugs elevate d&b& 
lation threshold. Class IC drugs are potent sodium channel 
blockers, as evidenced by prolongation of QRS duration at 
therapeutic doses indicating slowing of conduction through 
nomtal ventricular muscle. In a controlled study in dogs 
using implanted electrodes, Fain et al. (IS) demonstrated 
that encainide and one of its active metabcdites cause a 
significant elevation in ventricular defibrillation threshold. In 
the present study we used similar methods to evaluate the 
effect of recainam on defibrillation threshold in anesthetized 
dogs. We have also correlated the dose-dependent e5ects on 
defibrillation threshold with electrophysiologic effects on 
QRS duration and with plasma recainam levels. 
Methods 
Experimentat preparation. Seventeen male mongrel dogs 
weighing I4 to 23 kg (mean 17 kg) were anesthetized with 
intravenous odium pentobarbital (30 mgikg body weight): B Detibrillation threshold dctermtnation. Ventricular fibril- 
maintenance dose of 5 mglkg per h of sodurn pentobarbrtal lation was induced by delivering a IOOmslrrdnof4 ms pulses 
was used to maintain surgical anesthesia. Babbs (22) haa ~1 In0 Hz during the vulnerable period after I2 ventricular 
shown that sodium oentobarbital has no swnificant eR‘ect on paced beats. We attcmoted to defibrillate mine truncated 
ventricular defibrillation levels. The dogs w&e intobated and 
ventilated using a Harvard resp~ator. A catheter was placed 
in the femoral artery to monitor blood pressure. The femoral 
vein was also cannulated for the infusion of saline solution 
and recainam. 
The chest was opened b. a median sterootorov. aod rhe 
heart suspended io.a per&dial cradle. Two b&Jar clec- 
tmdes were sutured to the right ventricular epicardium to 
pace the ventricles and to administer fibrillating pulse trains. 
A third bipolar electrode was utored to the riahr ventricular 
epicardiu& at a distance from the pacing ittd fibrillating 
electrodes to record ventricular activation and determine the 
ventricular effective refraclorv oetiod. 
A titanium apical patch e&ode (13.5 cm’) (Intec-CPI) 
was sutured to the anterior and lateral surfaces of the left 
ventricular epicardium near the apex. A titanium opting 
electrode (Intec-CPI) was introduced into the left external 
jugular vein and the tip positioned at the junctioa of the 
superior vena cava and right atrium The chest wz,s then 
closed with towel clamps. 
Electrocardiographic (KG) leads 1. I1 and Iii. aruial 
blood pressure and a local ventricular electragram were 
monitored with a 51 I I Tektronics oscilloscope and recorded 
on a 28 channel Honeywell IO1 tape recorder and an eight 
channel Siemens-Elema Mingogsaph recorder. Arterial 
blood gases were measured after completion of the surgical 
procedures, at the beginning of the control and infusion 
periods and periodically during the experiment as needed. 
Arterial pH was maintained between 7.33 and 7.43. Arteria! 
partial pressure of carban dioxide Pcq was maintained 
behveen 33 and 43 mm Hg. lntrathoracic temperature was 
maintained between 38 and 3YC. This study coofons to the 
Position of the American Heart Association on Research 
Animal Use. The protocol was approved by the Institutional 
Animal Care and Use Committee of the University of 
Pennsylvania. 
Eleclmphyrlologic measurernot% QRS duration was 
measured from recordings of ECG leads I, II and III at a 
paper speed of 250 mmis. during normal sines rhythm and 
during right ventricular pacing at a cycle length of 250 ms. 
Ventricular effective refractory period was defined as tbe 
longest coupling interval of a premature stimolos that failed 
to capture after I2 ventricular paced beats at a basic cycle 
length of 2.50 ms. It was detemtined to within I ms using a 
stimulus strength twice the diastolic threshold delivered to a 
bit&r right ventricular electrode that was not used for 
pacing d&g any other part of the study. The diastolic 
threshold was redetermined before each measurement of the 
ventricular effective refractory period. 
kxponentml shocks del&red from zm external cardiovener- 
defibrillax (Intec-CPI) between the apical patch and woe- 
rior vena FX”YB apringelectrode. We used this deftbrilloto; to 
deliver shocks at settings of 3.5. IO. IS, 20.25. 30.35 or 40 
joules. Data refer to soccess or failure of shocks at panicular 
settings. 
The wnr,icu,w de,ib,i,,arion threshold WQS described bv 
a curve relatmg the probability of successful defibrillation tb 
the energy oithe shock. Tbecorvewas constructed from the 
results of five test shocks delivered at each of at least four 
energy levels. Each test shock was delivered IO s after the 
onset of fibrillation. If a test shock was onsuccessfu! the 
hean was immediatelv defihrillated with a hi&r eoerw 
rescue shock. Only thk results of test shocks were used; 
determine defibrillation threshold. We waited at least 3 min 
after each detibrillatbo and until heart rate and blood 
pressure srz%lized before reinducing fibrillation. The range 
of test shocks to be used was determined bv star&-a with a 
25 joule test shock and then decreasing the energy of 
successive trials by 5 joules until a test shock was onsoc- 
cessiol. This energy level and three others (one lower end 
two higher) were then tried repeatedly in random order until 
each of the four levels was tried five times. lc the event hat 
the highest of the four energy levels was not successful in at 
least four of five trials, fbe leveljust above this level was also 
tested five times. The Dante procedure was repeated during 
the drug info&m to ensure that he range of energy levels 
included low values that were rarely successful and high 
values that were usually successful. 
Pmtocd. In each experiment defibrillation threshold was 
determined during a control period and again durirtg an 
infusion period. QRS duration and ventifular effective 
refectory period were measured at the beginning and the 
end oithe control period(toassessthestability oithisperiod 
and for comparison with the infusion period). During the 
infusion rxriod a kmdine dose of saline solution or reeainam 
was i&ed over20 min~a lower maintenance dose wao then 
infused for the remainder of the experiment. The QRS 
duration, diastolic threshold and ventricular effective refmc- 
tory period were measured beginning 25 min into the infu- 
sion period (that is, 5 min into rhc maintenance infusion) and 
again at the end of Ihe protocol. These times precede and 
follow the redetermination of defibrillation tbreshcld during 
the infusion. 
Infusions. Tbe dogs were clraified into three groups: a 
saline group (n = 6). a low dose recainam tqottp (n = 6) and 
a high dose re-minam group (n = 5). The saline group 
received an infusion of saline solution. The low dose recai- 
nom group received an intravenous loading infusion of 3.75 
m@kg of this agent (dissolved in saline solution) over 20 min 
and a maintenance infusion of 0.0375 mgJkg ner min for the 
remainder of the experiment. The high dasc rccainsm group 
received a loading daac of 7.5 &kg over 20 min and a 
mamlenance mfusion ofo.075 mg!kg per mm. The volomc of 
sahne solution infused was the same for all croups. 
Plasma recsinam levels. Arterial blood-samples were 
drawn 5 min after the start of the maintenance infusion (25 
min after the stali of the infusion period) and again at the end 
of each experiment for determination nf recainam concen- 
tration. In some exoeriments an additional blood s~mole wa$ 
drawn 20 min after the ttart of the maintenance infusion. 
Blood samplcs were hcparinized and centrifuged and the 
plxma wa; frozen. The-plasma samples were &+&cd for 
recainam using high performance liquid chromatography us 
previously described (R). 
Statistics and analysis. For each experimental per!od the 
percat of de:,brillation trials ihat were successful et each 
energy level was fit !o a srgmoid dose-response curve using 
locistic rewssicn. Becwse observed probabilities of 0 and 
1.i could-othcrwsc not I,e used for ihis regression, they 
were changed to 0.05 and 0.95 for the regression, a procc- 
dure adapted from that suggesied by Armitagc (231 for 
probabilities estimated from small samples. If more than one 
energy level on the high end of the tested range was 
successful in five of five trials. then nnly the probability at 
the lowesl of these energy levels wa, reduced to 0.95 for the 
regression. E,, and E,O~indtcate the cncrgy required for 50 
and 80% probability of swceasful defibrillation, rcspcc- 
lively. determined from the logistic regression. AII data arc 
presented as mean z SE. Paired t tests were used to evaluate 
changes in QRS and ventricular effective refractory period 
during the control periods and changes in recainam conccn- 
nation during the infusion period. 
For statistical comparison of the change in defibrillation 
energy requirements in the three group3 we used E,, as the 
single be%! indicator of the position of the probability disrri- 
bution. The mean changes in E,, (in joules) for each of the 
three groups were compared using one-way analysis of 
variance. Then Tukey’s test was used to evaluate the signif- 
icance of differences between pairs of groups. Values of p < 
0.05 were considered significant. The values for percent 
change in Table I were calculated before rounding off the 
data for control and infusion periods. Correlations were 
evalualed using least squares linear regression. 
Stability of ekctrophysiologic variables during experimen- 
tal periods. We meawed QRS duration and ventricular 
effective refractory period at the beginning and the end of 
each experimental period (control and infusion) to determine 
whether these variables changed systematically because of 
repeated delibrilldtions or tLr pasag< of 60 LO W min 
required to evaluate defibrillation Ihrcshold. The chnnge in 
ELcdvc Xefncmry Pcrial and i)cfihrillation Energy 
QRS duration during sinus rhythm from the beginning to the 
end of the control priods for the three experimental groups 
was -0.3 * 1%. The corresponding change in QRS duratton 
during ventricular pacing was -0.7 ? 0.6%. Neither change 
was statistically significant. The ventricular effective refrac- 
tory period also did not change significantly during the 
control periods. Furthermore. in the saline group there was 
no significant change in QRS duration or ventricular et&- 
tive refractory period from the beginning to the end of the 
infusion period. These data indicate no systematic changes 
in electrophysiologic variables during our experimental pc- 
riods in the absence of drug infusion. 
In borh rmainam-rreored groups the QRS duration was 
not significantly different at the beginning and the end of the 
maintenance infusion of recainam. During sinus rhythm the 
change in QRS duration was -1.6 + 2% and -2.3 i 4% for 
the low dose and the high dose group. respectively. The 
change in paced QRS duration was -0.8 * 0.5% and 2.9 ? 
4% for the low and the high dose group, respectively. These 
values indicate a relatively constant dlug etkt on condw- 
tion during the period when defibrillation energy require- 
ments were measured in the presence of rccainam. The 
followingdata. showing the tTec;s ofdrug or saline mfusion. 
compare measurements at the end of the control period wilh 
,ncasur<mcnt~ at the end of the infusion period. 
R&Mm plmma cancentratioas. Recamam plasma con- 
centration at the end of the maintenance mfusion period was 
3.2 f 0.3 &nl in the low dose group and 7.7 L_ 0.9 &nl in 
the high dose group. Fiwre I shows ,he consistency of 
recanam pIa& concen&anr bctwecn Ike beginning and 
the end OF rhc maintenance infusions far the high and low 
dose gmups. In the low dose group. blood samples were 
drawn at bath 5 afid I5 min after the load& infusion to 
determme if5 min was sufficient time to reach a-steady State. 
There was a small decrease in rccainam concentration duiing 
this imewal. There W&E no signitican. change between the 
second and the last blood sample durmg rhr lime defibiilla- 
tion threshold was marured. 
ERwts of recainsm oi snlim infusion on QRS duration, 
sinus cycle length, ventricular ellective r#rwtory period and 
blocd p,ewwe, Table I shcws the meawed QRS duration 
mod perceni ckangc in QRSdqr&n bctueen rkecomroland 
infusion oeriod~ in the three crows during sinus rhythm and 
during pacing. In the saline g&, the inf&n did not result 
in a sirnificant change in ORS duration during sinus rhythm 
u, d&g pacmg. Thcrc ias a significanr difference among 
the rhree groups in the change in sinus QRS dura,:on 
between ihe control and ;,&ioo p&ads using ~ee+z: 
analysis of variance. Pared camparisonr showed the pc,cent 
change in each recainam group to he w&candy greater 
than in the saline control group. Although the mean percent 
change in the high doze recainam group (27 ? 7%) was 
greatc, rban in the low dose recainam group (I I 2 3%?. ;hc 
difference did not reach arislical significance. fdenrical 
:,atemcnts rcgardinp statis,,crd significance apply to the 
change in QRS duration during pacing. 
The s,““s rycle lengths were 367 + 9.350? IS ad 348 * 
16 ms in the conlrol periods and 312 2 13.360 ? 13 and 367 
z 21 ms in the infusion oer,cds for the saline. the low dose 
and the high dose rccainam ?KNJ~, respectively. Tbc differ. 
ewes among comparabbz period; in the three-groups were 
not zigniiicanr using one-way walyris of variance. In addi- 
tion. Ike chwnge in cycle length between ,he control and 
infunon periods was no! significant in any group as assessed 
by paired I ~a&. The infusmn caused M) sigmficanr change 
in ventricular effective refractory period in any grxp (Table 
I). 
Bloorl prprrwe was nor r~gnifconrly differeerenr during the 
tvnml pmod> in rhr tltree grwp. bfean blocd ivesrurc 
was KM i 4. IO7 * 5 and 101 - 4 mm Hg in the saline. low 
dose and hngh dose rccainam gnup. respectively. Between 
c~ntml and tnfusion periods !hc,e were small decreasco in 
mean blood pressure af IO z 2, 4 + 3 and 9 ? 4 mm H&L 
respectively. lbat nnly reached slatistical significance in the 
saline group (p&d t t&). 
EB& of inhsions on deflbrlllatbn thmhold. Figure 2 
shows the curves lit to the defibrillation data from a rcpre- 
sentativr e:+&ment in the low dose recainam group. Within 
rack pcrmd there was an increase in percent s~cccss with 
increasmg energy. The rccamam infusion WIE associated 
wi!k a shift ,n the dcse-recpenx rciarinn to the ri@<, tflward 
higher energy levels. 
Menr, drr,aforE,ond &,(rhr energy requiredforS0 on: 
80% .mcwssJid d~Jibrillorion) in each group are shown in 
Table I In the saline gnup there was no significant changr! 
in the energy required for defibrillation between the conlr~l 
and infusion periods fEin = 8.S ? 1.4 versq~ 6.6 + 1.6 
dru: e5ccts on conduction 0s manifested by chaoges in QRS 
duration. The higher dose infusion produced higher plasma 
drug Icvels and greater ekvotion of defibrillation threshold. 
These results suggest hat mapitode of the drug effect on 
QRS duration may be useful a, a rough indicator of the 
magmtude ot effect on defibrillation threshold and that 
reducing the dose could attenuate an wxcceptable elevation 
of defibrillation threshold. 
Relation b&ween sodium channel bkxkade and elevation of 
-* defibrillation threshold. The correlation between the effect 
WNE Low WSE HIC” oosf of rccainam on QRS duration sod defibrillation also has 
Wwe 3. The percent change in energy assoaated wth SD% suc- implications for the mechanism for the elevation of defibril- 
cersful delbnllatton &,I t+ SE) between conlmt and recainam or lation threshold by class I drugs. Babbs (21) hypothesized 
saline infusion periods for each of the three groups. that the reduction of sodium current, in itself. by reducing 
significant. The low dose i&ion produced a chin& in E,, 
of3.2 z t.Ojoule>. whersas the high dose infusion produced 
joulesl. Rccainam produced an increase in E<, in both the 
a greater change in E,, 019.2 + I .Ojotdes. These reoresent 
percent incr&ses of.42 and 92%; respectively (Fig. 3). 
low dose and high dose group. The change in E,, was 
Similar chances for E... and E... in each erouo indicate that 
the slope of;he dose&po&curver d;d not change in a 
significantly dilferent amon_c the three groups using analysis 
systematic way beween control and infusion periods. 
of variance: each oair of comoarisons between ~rouos was 
excitability. could explain the elevation of defibrillation 
threshold. However. in the study of Fain ?t al. (IS) the 
hypothesis. althl ugh the correlation does not prove a cawe 
and effect relatitm between sodium channel blockade and 
elevation of defibrillation threshold by encainide did not 
elevation of delitillation threshold. 
correlate with the degree of conduction slowing or plasma 
levels, findings l’lat appear to be inconsistent with Babbr’ 
hvoothesis. In c ontrast. our data are consistent with the 
I. 
Effectl. of other antirrrhythmie drugs on detibrilllntion 
threshold. Several type 1 antiarrhythmic drugs have been 
shown to increase defibrillation threshold in dogs, although 
results have varied depending in pan on the doses used. 
Woolfolk et al. (9) showed that quinidins can elevate defi- 
brillation threshold, but the experimental pmtoccl did not 
quantify the magnitude of the effect. Babbs et al. (IO) 
showed that quinidine gluconate increased the energy re- 
quired for defibrillation by 172% when a very high dose was 
administered. In contrast. there are two report= <I 1.16) that 
procainamide does not elevate defibrillation threshold at 
doses that oroduce olasma concentrations between 10 ad IS 
&ml. S&en1 &ties (lO.l2-14,17) have found that lido- 
Caine can increase defibrillation threshold. althoueh one of 
these studies (I?) suggested that the e5ect was modest in 
dogs anesthetized with chloralose rather than pentobarhital. 
There ws a significant correlation between the percent 
change in QRS duration during sinus rhythm and the eleva- 
lion of E,, using linear regression (r = 0.81, p < O.oWI). 
There was also a sienificant correlation between the recai- 
nam concentration 2 the end of the infusion and the eleva- 
tion of Era (r = 0.78, p < 0.01 using the II recainam 
experiments; I = 0.87. p < O.CQOI. using all experiments). 
Discussion 
This study dcmonstratcs that recainam, at therapeutic 
doses. elevates the energy required for ven~icula.r defihril- 
lation. In humans. the therapeutic plasma concentrations for 
suppression of premature ventricular complexes and com- 
plex ventricular ectopic aclivity have averaged I.66 to 3.0 
&ml in various aoldies ll.4.51. A dose-finding study (4) 
showed that a dose that produced 79% suppression of 
premature ventricular complexes and 98% suppression of 
repetitive forms produced a 14% prolongation of QRS dura- 
tion. This physiologic c5cct corresponds moot closely with 
that of our low dose recainam infusion. In lhia group 
In contrast. several investigators (12.13,24.25) have 
shown that brctylium. a class 111 drug. decreases or pro- 
Jutes no change in defibrillation threshold. Conflicting re- 
sults have been reported on the effect of amiodarooc. Two 
studies indicated that short- (26) or long-term (27) adminis- 
ration of amiodarone elevates defibrillation threshold. but 
another study, (28) found no change in defibrillation thresh- 
old after either short- or long-term administration. 
Comoarixm ui recaloam and encninide. The orohle of 
ventricular dehbnllation ihwhold was incrcascd b; 3.‘2 recainam’s effects on ventricular conduction and refractori- 
joules or by 42% above tbc coolrol YBIUO. ness in this study verifies its classification BE a class IC 
Bose-dependent effects of reeainam on defibrillation tbrerh- antiarrhythmic drug (8). At therapeutic concentrations it 
old. We also demonstrated that the e5ect of rccainam on prolonged QRS duration hut had no effect on duration of the 
ventricular defibrillation threshold is dose dependent and ventricular elctive refractory period. It is, therefore, rele- 
correlates with plasma rccainam concentration and with vttot to compare the effects of recainam on defibrillation 
threshold with those of other lr anfia~hyihm~c drug,. Fam elev:~~e dehhnllation threshold may be freqoendy and appro- 
et al. (15) reported that encainide and one of itr merabolite~. pr~alcly wed m patienls with an ~mplocted aotomat~ defi- 
O-demethyl-enrainide. significanlly elcv3ted defibrillation h:~il.oor m order to decrease the number of episodes of 
threshold in pentobarb!tal ane\thedzed dogs. The perccm wmnculi~ krhycardia or dbrillalion. The rewbs of our 
increase in defibrillation threshold m !hat study as well a, ~hc study wggexr lbal recainam nay elevate dcfihrillatton 
amount of ORS srclonaa!ion %‘8~- eoxa::nb!f .A’! Ibat oi Ihrc4wld m oaiieots with life-threateninc arrhvthmiar. . 
the higher dose of re&wr. For m&nide that dwr wit\ Whether wch Lo elkct is clinically importan;for a pkticular 
said to produce effects on QRS durmon compw~hlc with pmcnt WIII dcpcnd on rhe extcnl of Ihe safety margin for 
those of themoeuu~ doses m human<. tncamide cared defihrdlatnon no the drwfree slate. 
resistance to d&hrillation in %ome dogs. WC drd nor ohscrvc 
that with recainam. 
Conpuriwn of reruintm and e~wr~ride k facilil~ted by 
the similarity of the methods used m our study rmd lbat bv 
Fain et al. (IS). Both studier utilized lhr implanlable I;fl 
ventricular patch and superior vena cwa iprm: electrodes 
used in patients with the automatx lmplmtable cardioverkr- 
defibrillator (Intec-CPI). Furthermore. tbe protocol for eval- 
uating defibrillation lhreshold in our study wa$ modeled afkr 
the one used by Fain et al. The Ialle’ mvesugators I28.29) 
have emoharized that defibrillation threshold should be 
expressed in terms of a dose-response relation rekting the 
percent of successful delibrillationn to the energy delivered 
because there is no absolute and reproducible energy thresh- 
old that separates successful from unwcscsrful defibrdlatlon 
trials. We also found this approach useful. One meth- 
odologic difference was that Fain et al. (15) used the same 
range of energy levels after drug admimstrarmn lhat they 
used in the control period. This led to underestimation of the 
change in E, (the energy associated with 5G% wccevfol 
defibrillation) in a few experiments with the greatest drug 
effect in which the highest energy level was never successful 
in the presence of drug. To avold this problem we rcdelcr- 
mined the range of energy levels to be tested during the drug 
infusion. 
Role of cake studi of defibrillation threshold. Canine 
experiments have been used to evaluate drug elierts on 
defibrillation threshold because properly controlled studies 
involving repeated episodes of fibrillation and defibrillation 
are impractical in patients. Howevar. when relating the 
re~uhs of animal studies 10 oalienls several factors musl be 
considered. First, differ&s such as hean size (30) and the 
presence of ischemia or infarction (31.32) may affect the 
absolute energy required for defibrillation. Second. il is not 
clear how drug effects on defibrillation threshold in dog> 
should be scaled for humans. Ir is plausible to postulate thal 
the percent increase in defibrillation would be comwrable in 
pat& despite a higher baseline threshold. hut th;s has not 
been demonstrated experimentally. 
Conelusions. The results of conrrolled animal studies are 
useful for quantitative comparison of the effectr of drugs on 
defibrillation threshold among rxprr~menlal rtudier usmg 
similar protocols. They 81s” may suggest possible drug 
effects on defibrillation threshold in patirntr that may bc 
relevnnt and require evaluation in each patient. Drug5 that 
cardiovrrrion. 
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